Eli Lilly said the FDA has approved insulin efsitora alfa-gobe, which will be sold as Onswik in the U.S., for adults with type 2 diabetes. The company framed the product as a way for patients to receive more than 300 fewer injections per year than with daily insulin regimens.
The approval creates a fresh competitive matchup with Novo in diabetes, this time in once-weekly insulin. Earlier this year, Novo’s Awiqli became the first once-weekly insulin medicine available in the U.S., giving Lilly a fast-following entry rather than a first-mover advantage.
The Clinical Case
Lilly said Onswik was tested in 3,400 adults in the Phase 3 QWINT clinical trials. Those studies showed non-inferiority to standard once-daily insulin options, including insulin glargine and insulin degludec, which Novo markets as Tresiba.
In QWINT-2, Lilly said Onswik lowered A1C by 1.34%, compared with a 1.26% reduction in patients who took degludec. The company presented those results at the Annual Meeting of the European Association for the Study of Diabetes in September 2024.
The new U.S. label also draws a boundary around use. Lilly said Onswik should not be used in patients with type 1 diabetes because of an increased risk of low blood sugar.
The Commercial Picture
This is the fourth global approval for Onswik after clearances in Europe, Mexico and Japan, and Lilly said the product will be available in the U.S. in the coming months. That timing matters because Novo is already on the market with Awiqli after winning FDA clearance in March.
For Lilly, the signal is less about opening an entirely new category than about preventing Novo from owning it. Weekly dosing could be commercially meaningful if patients and prescribers treat fewer injections as a practical adherence benefit, but the near-term contest now depends on how quickly Lilly can convert approval into actual launch execution.
Awiqli’s path also shows the category is still being defined at the label level. Novo reached approval after two FDA rejections in 2024 tied to a type 1 diabetes request and manufacturing concerns, then refiled in September 2025 seeking a type 2 indication. Onswik now enters that same U.S. market with its own warning against type 1 use, while Awiqli’s label carries warnings about using the drug with low blood sugar.
